Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 5 of 5 entries
View as:

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Phase: N/A Priority: Normal
NCT ID: NCT04981119 Org: User:
Start: 10/29/21 End: 12/31/26 Due: 12/31/27

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Phase: N/A Priority: Normal
NCT ID: NCT05736731 Org: User:
Start: 04/28/23 End: 12/31/26 Due: 12/31/27

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Phase: N/A Priority: Normal
NCT ID: NCT06682793 Org: User:
Start: 05/22/25 End: 03/31/30 Due: 03/31/31

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Phase: N/A Priority: Normal
NCT ID: NCT06051695 Org: User:
Start: 04/03/24 End: 06/30/29 Due: 06/30/30

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Phase: N/A Priority: Normal
NCT ID: NCT06885424 Org: User:
Start: 08/31/25 End: 03/31/40 Due: 03/31/41